Sunitinib (Sutent®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000356
English
Authors' recommendations:
Sunitinib (Sutent®) is recommended for use within NHS Wales for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. Experience with sunitinib as a first-line treatment is limited.
AWMSG is of the opinion that sunitinib (Sutent®) is not suitable for shared care within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=180549&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Indoles
- Pyrroles
- Antineoplastic Agents
- Neuroendocrine Tumors
- Pancreatic Neoplasms
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.